+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

The Corporate Reputation of Pharma in 2021 - The Patient Perspective - Italy Edition: The Views of 103 Italian Patient Groups

  • Report

  • 59 Pages
  • September 2022
  • Region: Italy
  • PatientView
  • ID: 5455969

The ‘Corporate Reputation of Pharma’ survey - the 2021 Ital edition is now in its 8th year, and two years into the Covid-19 pandemic. Between November 2021-February 2022, the survey collected the opinions of 103 Italy-based patient groups on the performance of the pharmaceutical industry during 2021.

Patient groups possess a unique understanding of the needs of the patients and represent their collated views. Patient-group perspectives have become increasingly important to regulators that demand patient input into trial design and conduct, as well as into the evaluation of clinical outcomes. At the same time, many patient groups are also familiar with the complexities of pharma’s business. From their vantage point, therefore, patient groups are both able to assess pharma, and recommend ways in which companies can improve - all from a patient perspective.

2021’s 103 respondent Italian patient groups had, collectively, been in communication with 959,000 Italian patients during the year. 76% of the Italian patient groups responding to the 2021 ‘Corporate Reputation of Pharma’ survey worked or partnered with at least one pharma company that year. 

The report provides details on: 

  • How the analyst measures pharma’s corporate reputation from a patient perspective; 
  • The headline results of the 2021 Italy element of the ‘Corporate Reputation’ survey; 
  • The companies included in the 2021 Italy analysis; and 
  • The profiles of 2021’s respondent Italian patient groups. 

Companies assessed for corporate reputation in the 2021 Italy report 

AbbVie, AstraZeneca, Bayer, Biogen, Boehringer, Ingelheim, Bristol Myers Squibb, Chiesi Farmaceutici, Eli Lilly, Gilead Sciences, GSK, Janssen, Menarini, MSD, Mylan, Novartis, Novo Nordisk, Pfizer, Roche, Sandoz, Sanofi, Takeda and Teva 

COMPANY RANKINGS IN ITALY IN 2021 

  • The top-three pharma companies in Italy in 2021, out of 22 companies, ranked for their overall corporate reputation (as assessed by respondent Italian patient groups familiar with the company): Roche, 1st - Novo Nordisk, 2nd - Pfizer, 3rd.
  • The top-three pharma companies in Italy in 2021, out of 6 companies, ranked for their overall corporate reputation (as assessed by respondent Italian patient groups working with the company): Pfizer, 1st - Roche, 2nd - Novartis, 3rd. 
  • The top-three ‘big-pharma’ companies in Italy in 2021, out of 12 ‘big-pharma’ companies, ranked for their overall corporate reputation (as assessed by respondent Italian patient groups familiar with the company): Roche, 1st - Pfizer, 2nd - GSK, 3rd. 
  • The top-three ‘big-pharma’ companies in Italy in 2021, out of 5 ‘big-pharma’ companies, ranked for their overall corporate reputation (as assessed by respondent Italian patient groups working with the company): Pfizer, 1st - Roche, 2nd - Novartis, 3rd. 

Table of Contents


1 Executive summary
11 Italian patient-group relationships with pharma
14 Industry-wide findings
20 The corporate-reputation rankings of 25 pharma companies, 2020 (v. 2019), as assessed by Italian patient groups familiar with the companies
36 The corporate-reputation rankings of 5 pharma companies, 2020, as assessed by Italian patient groups that work/partner with the companies
52 Profiles of the 25 companies, 2020 (v. 2019)
APPENDICES
I Profiles of respondent Italian patient groups, 2020
II  List of respondent Italian patient groups that wished to be attributed, 2020
III  What respondent Italian patient groups say about pharma (and how the industry can improve), 2020/2021

TABLES AND CHARTS
2 The thirteen indicators used to measure corporate reputation, 2020
3 Pharma’s corporate reputation in Italy has remained largely unchanged since 2014 (percentage of respondent Italian patient groups stating that the pharmaceutical industry has an “Excellent” or “Good” corporate reputation)
4 Covid-19 vaccine doses administered per 100 people in Western-European countries and the EU, as of February 28th, 2021
4 The effectiveness of the pharma industry at supporting patients during Covid-19, 2020 - by countries in Western Europe (percentage of respondent patient groups stating “Very effective” or “Effective”)
9 The overall rankings of 14 ‘big-pharma’ companies at corporate reputation in Italy, 2020 v. 2019 (as assessed by respondent Italian patient groups familiar with the companies)- ordered highest to lowest
10 The overall rankings of 5 ‘big-pharma’ companies at corporate reputation in Italy, 2020 (as assessed by respondent Italian patient groups that work/partner with the companies) - ordered highest to lowest
12 Respondent Italian patient groups: their familiarity, and partnerships, with pharma companies, 2020
13 The types of working relationships that respondent Italian patient groups have with pharma, 2020
15 The corporate reputation of the pharmaceutical industry, 2020 v. 2019 - compared with that of other healthcare sectors (percentage of respondent Italian patient groups stating “Excellent” or “Good”)
15 The corporate reputation of the pharmaceutical industry, 2014-2020 (percentage of respondent Italian patient groups stating “Excellent” or “Good”)
16 How good or bad the pharmaceutical industry was in 2020 v. 2019 at carrying out specific activities important to patients (percentage of respondent Italian patient groups stating “Excellent” or “Good”)
17 The pharmaceutical industry’s effectiveness at tackling Covid-19 in 2020 - Italy v. global (percentage of respondent patient groups stating “Excellent” or “Good”)
18 How good or bad the pharmaceutical industry was at carrying out specific activities important to patients, 2012-2020 (percentage of respondent Italian patient groups stating “Excellent” or “Good”)
20 The rankings of 25 individual pharma companies, 2020 v. 2019 - as assessed by respondent Italian patient groups familiar with the company
36 The rankings of 5 individual pharma companies, 2020 v. 2019 - as assessed by respondent Italian patient groups that work/partner with the company
52 Profiles of the 25 companies, 2020

CHARTS AND TABLES FOR EACH OF THE 25 COMPANIES
  • The number of respondent Italian patient groups familiar with the company, 2020.
  • The number of respondent Italian patient groups saying that they had a working/partnering relationship with the company, 2020.
  • The profile of the respondent Italian patient groups familiar with the company (the number of patients reached; specialties; and geographic remit), 2020.
  • The types of relationships that the company had with its Italian patient-group partners, 2020.
  • Company performance at the individual indicators of corporate reputation in 2020 - as assessed by respondent Italian patient groups familiar, and which partner/work, with the company.
  • Competitors’ relationships in 2020 with the respondent Italian patient groups with which the company partners/works.
  • Overall rankings for the company - as assessed by respondent Italian patient groups familiar with the company, 2020 (v. 2019).
  • Overall rankings for the company - as assessed by respondent Italian patient groups that work/partner with the company, 2020 (v. 2019).
  • Company rankings for each of the indicators of corporate reputation - as assessed by respondent Italian patient groups familiar, or working, with the company, 2020 (v. 2019).
  • Snapshot view: where the company sits in the corporate tiers for each of the indicators (in the higher, the middle, or the lower tier) - as assessed by respondent Italian patient groups familiar with the company.
  • The company’s overall Patient Corporate Reputation Index (PCRI), 2015-2020, as assessed by respondent Italian patient groups familiar with the company.

Samples

Loading
LOADING...

Companies Mentioned

  • AbbVie
  • AstraZeneca
  • Bayer
  • Biogen
  • Boehringer
  • Ingelheim
  • Bristol Myers Squibb
  • Chiesi Farmaceutici
  • Eli Lilly
  • Gilead Sciences
  • GSK
  • Janssen
  • Menarini
  • MSD
  • Mylan
  • Novartis
  • Novo Nordisk
  • Pfizer
  • Roche
  • Sandoz
  • Sanofi
  • Takeda 
  • Teva 

Methodology

Loading
LOADING...